Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

Fig. 2

Frequency of EGFR amplification (amp), PTEN deletion (del), TERT promoter mutations (mut) and MGMT promoter methylated samples in the distinct glioma molecular subgroups. EGFR amplification was analyzed: in 227 GBM-IDH wildtype, 9 GBM IDH-mutant, 48 1p/19q codeleted gliomas, 35 Astrocytoma IDH-wildtype, 53 Astrocytomas IDH-mutant. PTEN deletion was analyzed: in 225 GBM IDH-wildtype, 7 GBM IDH-mutant, 48 1p/19q codeleted gliomas, 37 Astrocytoma IDH-wildtype and 53 Astrocytoma IDH-mutant. TERT promoter mutations were analyzed: in 124 GBM IDH-wildtype, 4 GBM IDH-mutant, 49 1p/19q codeleted gliomas, 41 Astrocytoma IDH-wildtype, 51 Astrocytoma IDH-mutant. MGMT methylation was analyzed: in 235 GBM IDH-wildtype, 10 GBM IDH-mutant, 49 1p/19q codeleted gliomas, 41 Astrocytoma IDH-wildtype and 54 Astrocytoma IDH-mutant

Back to article page